With readouts from three clinical trials expected in 2016, next year will be a critical one for Tonix. First will be data from a Phase II study for TNX-201 (R-isomer of isometheptene) in Q116 for episodic tension-type headache (ETTH), which may offer an effective and non-addictive option. Next will be data from a Phase II trial for TNX-102 SL in H116 for post-traumatic stress disorder (PTSD), where current medications have spotty efficacy. Finally, the Phase III for Tonmya (TNX-102 SL) in fib
07 Dec 2015
All systems go for 2016
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
All systems go for 2016
With readouts from three clinical trials expected in 2016, next year will be a critical one for Tonix. First will be data from a Phase II study for TNX-201 (R-isomer of isometheptene) in Q116 for episodic tension-type headache (ETTH), which may offer an effective and non-addictive option. Next will be data from a Phase II trial for TNX-102 SL in H116 for post-traumatic stress disorder (PTSD), where current medications have spotty efficacy. Finally, the Phase III for Tonmya (TNX-102 SL) in fib